Clinical trial
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
NCT00073593 · The Medicines Company, Industry · Completed
Key facts
| NCT number | NCT00073593 |
|---|---|
| Title | Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB |
| Official title | A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Coronary Artery Bypass (OPCAB) Surgery |
| Acronym | OPCAB |
| Lead sponsor | The Medicines Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardiac Surgery, Coronary Artery Bypass Surgery |
| Intervention type | Drug |
| Interventions | Bivalirudin, Heparin, Protamine |
| Enrollment | 150 |
| Start date | Aug 1, 2003 |
| Primary completion | May 1, 2004 |
| First posted | Nov 27, 2003 |
| Last update posted | Nov 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: